Status:
COMPLETED
Innate Immune Responses in Chronic Obstructive Pulmonary Disease (COPD) Patients
Lead Sponsor:
Mahidol University
Collaborating Sponsors:
National Science and Technology Development Agency, Thailand
Conditions:
Chronic Obstructive Pulmonary Disease
Eligibility:
All Genders
18-80 years
Phase:
PHASE3
Brief Summary
We hypothesize that ongoing and more severe airway inflammation in COPD may result from the impairment in activation of innate immune response
Eligibility Criteria
Inclusion
- clinical diagnosis of COPD or asthma
- a ratio of prebronchodilator FEV1 to forced vital capacity (FVC) equal to or less than 0.70
- postbronchodilator FEV1 \> or = 50% predicted
Exclusion
- Exacerbation
- systemic corticosteroids
- DM, HIV and autoimmune disease
- immunosuppressive therapy
Key Trial Info
Start Date :
January 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2009
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00826163
Start Date
January 1 2009
End Date
December 1 2009
Last Update
September 11 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kittipong Maneechotesuwan
Bangkoknoi, BKK, Thailand, 10700